PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction. It did not advance into clinical trials.
PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction. It did not advance into clinical trials.
== See also == List of investigational sexual dysfunction drugs ABT-670 ABT-724 Cabergoline Bremelanotide Flibanserin Intrinsa Melanotan II OSU-6162 PF-592,379 Pramipexole Tibolone UK-414,495
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).